Risultati per: Trattamento della sindrome dell'intestino irritabile (IBS)

E’ una condizione genetica ereditaria che aumenta il rischio di malattia oncologica

Recently in Gut, several reviews and reports have highlighted hypomorphic (dysfunctional) variants of the sucrase-isomaltase (SI) gene in relation to increased risk of irritable bowel syndrome (IBS), particularly the diarrhoea-predominant type (IBS-D).1–4 Similar to congenital (rare recessive) and acquired forms of SI deficiency, impaired SI enzymatic activity is expected to lead to colonic accumulation of undigested disaccharides, thus triggering IBS manifestations via gut microbiota fermentation, gas production and osmotic diarrhoea. Reduced efficacy of a diet low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) is also observed for SI hypomorphic IBS-D carriers,4 as this intervention may be suboptimal for individuals with possible defects in the digestion of carbohydrates other than FODMAPs (the lowFODMAP diet does not specifically restrict sucrose and starch, the substrates of SI disaccharidase activity). These results hold strong potential for personalising therapeutic (dietary) interventions in subgroups…

Si tratta della seconda terapia genica abbandonata dall’industria di cui la Fondazione non profit si fa carico affinché arrivi ai pazienti che ne hanno bisogno

Dalla Fondazione la sfida per renderla disponibile ai pazienti

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Un nuovo studio dell’Università Tor Vergata ne dimostra il ruolo benefico

Nuovo studio Università Tor Vergata ne dimostra ruolo benefico

Un nuovo studio dell’Università Tor Vergata ne dimostra il ruolo benefico

Tor Vergata è capofila come numero di interventi eseguiti

La spinta da una fondazione italiana